- Home
- CLLS vs GLSI Comparison
CLLS vs GLSI Comparison
Compare CLLS & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- GLSI
- Stock Information
- Founded
- CLLS 1999
- GLSI 2006
- Country
- CLLS France
- GLSI United States
- Employees
- CLLS N/A
- GLSI N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- GLSI Health Care
- Exchange
- CLLS Nasdaq
- GLSI Nasdaq
- Market Cap
- CLLS 143.4M
- GLSI 133.4M
- IPO Year
- CLLS 2007
- GLSI 2020
- Fundamental
- Price
- CLLS $1.58
- GLSI $9.27
- Analyst Decision
- CLLS Buy
- GLSI Strong Buy
- Analyst Count
- CLLS 1
- GLSI 1
- Target Price
- CLLS $4.00
- GLSI $39.00
- AVG Volume (30 Days)
- CLLS 50.1K
- GLSI 37.8K
- Earning Date
- CLLS 08-05-2025
- GLSI 08-13-2025
- Dividend Yield
- CLLS N/A
- GLSI N/A
- EPS Growth
- CLLS N/A
- GLSI N/A
- EPS
- CLLS N/A
- GLSI N/A
- Revenue
- CLLS $54,747,000.00
- GLSI N/A
- Revenue This Year
- CLLS $48.52
- GLSI N/A
- Revenue Next Year
- CLLS $5.17
- GLSI N/A
- P/E Ratio
- CLLS N/A
- GLSI N/A
- Revenue Growth
- CLLS 351.26
- GLSI N/A
- 52 Week Low
- CLLS $1.10
- GLSI $8.06
- 52 Week High
- CLLS $2.43
- GLSI $18.15
- Technical
- Relative Strength Index (RSI)
- CLLS 60.33
- GLSI 42.26
- Support Level
- CLLS $1.41
- GLSI $8.67
- Resistance Level
- CLLS $1.60
- GLSI $9.37
- Average True Range (ATR)
- CLLS 0.09
- GLSI 0.28
- MACD
- CLLS 0.02
- GLSI 0.00
- Stochastic Oscillator
- CLLS 83.52
- GLSI 28.74
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.